Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients
Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period
Sponsor: Institut de Recherches Internationales Servier
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Institut de Recherches Internationales Servier
- IDH1-mutant Cholangiocarcinoma · Phase PHASE1/PHASE2 · Nov 2024
- Advanced Solid Tumors · Phase PHASE1 · Apr 2023
- Chronic Uveitis · Phase PHASE3 · Nov 2015
- Behcet's Uveitis · Phase PHASE3 · Sep 2015
- Uveitis · Phase PHASE3
See all terminations from Institut de Recherches Internationales Servier
Other Mild Cognitive Impairment trials with similar outcome
A PHASE2 clinical study on Mild Cognitive Impairment, this trial is terminated or withdrawn. The trial is conducted by Institut de Recherches Internationales Servier and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jan 2017 — May 2017 [monthly]
Suspended PHASE2
First recorded
Jun 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut de Recherches Internationales Servier
For direct contact, visit the study record on ClinicalTrials.gov .